Neurotropic Cutaneous Tumors of the Head and Neck

Jd, Osguthorpe; Cg, Abel; Lang, P.G.; Hochman, Marcelo

doi:10.1001/archotol.1997.01900080105013

Cited by 32 publications

(49 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering large published series that encompass all 'ordinary' BCCs, it seems rather uncommon, oscillating from 0.19% [15] to 0.49% [16] . Some authors reported an increased frequency of 3.8% in cancers treated by Mohs' micrographic surgery [17] .…”

Section: Introductionmentioning

confidence: 99%

Perineural Invasion in Aggressive Skin Carcinomas of the Head and Neck

Cernea¹,

Ferraz²,

Castro

et al. 2008

ORL

View full text Add to dashboard Cite

Introduction: Perineural invasion is a well-recognized form of cancer dissemination. However, it has been reported only in few papers concerning cutaneous carcinomas (basal cell, BCC, and squamous cell, SCC). Moreover, the incidence is considered to be very low. Niazi and Lambert [Br J Plast Surg 1993;46:156–157] reported only 0.18% of perineural invasion among 3,355 BCCs. It is associated with high-risk subtypes, as morphea-like, as well as with an increased risk of local recurrence. No paper was found in the literature looking for perineural invasion in very aggressive skin cancers with skull base extension, with immunohistochemical analysis. Methods: This is a retrospective review, including 35 very advanced skin carcinomas with skull base invasion (24 BCCs and 11 SCCs, operated on at a single institution from 1982 to 2000). Representative slides were immunohistochemically evaluated with antiprotein S-100, in order to enhance nerve fibers and to detect perineural invasion. The results were compared to 34 controls with tumors with a good outcome, treated in the same time frame at the same Institution. Results: Twelve (50.0%) of the BCCs with skull base invasion had proven perineural invasion, as opposed to only 1 (4.6%) of the controls, and this difference was statistically significant (p < 0.001). Regarding SCCs, 7 aggressive tumors (63.6%) showed perineural invasion compared to only 1 (10.0%) of the controls, but this difference did not reach significance (p = 0.08), due to the small number of cases. Conclusions: In this series, it was demonstrated that immunohistochemically detected perineural invasion was very prevalent in advanced skin carcinomas. In addition, it was statistically associated with extremely aggressive BCCs with skull base invasion.

show abstract

Section: Introductionmentioning

confidence: 99%

Perineural Invasion in Aggressive Skin Carcinomas of the Head and Neck

Cernea¹,

Ferraz²,

Castro

et al. 2008

ORL

View full text Add to dashboard Cite

show abstract

“…Both patients had intracranial disease extending through a peripheral foramen but had refused an intracranial operation. 602 No deaths attributable to SCC after ART treatment for perineural invasion were reported in any of the remaining three studies (16 patients). 598,600,601 Three studies (comprising 21 patients) addressing ART of other SCCs had data on patient deaths, with one reporting the death of three patients out of six who had post cardiothoracic transplant SCCs between 8 months and 54 months after diagnosis.…”

Section: Adjuvant Radiotherapymentioning

confidence: 84%

“…Metastasis to the skull 1 year after treatment was reported in one patient with symptomatic perineural invasion affecting the supraorbital nerve in a further series. 599 In the other three studies, two of which included patients with asymptomatic perineural invasion in unnamed nerves 598,601 and one in which there was involvement of named cranial nerves, 602 there were no reports of recurrence following treatment during follow-up ranging from 10.4 months to 104.8 months.…”

Section: Adjuvant Radiotherapymentioning

confidence: 98%

See 1 more Smart Citation

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

“…As taxas de recidivas dos CECs operados pela CMM variaram de 2,3% a 10%, e as de metásta-ses variaram de 0,5% a 16%, segundo dados dos estudos de Rowe, Cherpelis e Osguthorpe. 6,23,24 Conforme o estudo de Rowe, ambas foram menores que as encontrads nas outras modalidades terapêuticas, que demonstraram recidivas de 3,7% a 47,2% e metástases de 5,2% a 47,3%. 6 Na análise estatística univariada dos fatores preditivos do número de estádios cirúrgicos na CMM apenas a condição de recidiva mostrou tendência a maior número de estádios (p = 0,08) (Tabela 4).…”

Section: Discussionunclassified

Fatores preditivos do maior número de estádios na cirurgia micrográfica de Mohs para o tratamento do carcinoma espinocelular da cabeça

Terzian

Neto

Pimentel

2008

An. Bras. Dermatol.

View full text Add to dashboard Cite

Resumo: FUNDAMENTOS -Os carcinomas espinocelulares da pele da cabeça têm como opção terapêutica mais segura a cirurgia micrográfica de Mohs, que apresenta os menores índices de recidiva e a máxima preservação tecidual. Características dos carcinomas espinocelulares podem estar relacionadas a maior número de estádios cirúrgicos. OBJETIVO -Definir características dos carcinomas espinocelulares que sejam preditoras de maior número de estádios na cirurgia de Mohs. MÉTODOS -Análise retrospectiva de 51 carcinomas espinocelulares da cabeça tratados pela cirurgia de Mohs para determinar fatores de risco de maior número de estádios. Foram analisados limites clínicos, morfologia, recidiva, histologia e tamanho, relacionando-os ao número de estádios cirúrgicos. A análise estatística foi realizada pelo teste exato de Fisher e regressão logística multivariada. RESULTADOS -Os carcinomas recidivados tiveram tendência a maior número de estádios (p=0,081). Os tumores com limites imprecisos apresentaram três vezes mais possibilidades de maior número de fases na análise da razão de chances. Esse achado foi compatível com dados da literatura, apesar de não ter sido estatisticamente significante. CONCLUSÃO -Características pré-operatórias dos carcinomas espinocelulares, como recidiva e limites imprecisos, apesar de não preditivas, indicaram tendência a maior número de estádios na cirurgia micrográfica de Mohs. Palavras-chave: Carcinoma de células escamosas; Cirurgia de Mohs; Diretrizes para a prática clínica; Neoplasias cutâneas; Neoplasias cutâneas/tratamento; Neoplasias de cabeça e pescoço Abstract: BACKGROUND -Squamous cell carcinomas of the skin of the head are better treated with

show abstract

Neurotropic Cutaneous Tumors of the Head and Neck

Cited by 32 publications

References 24 publications

Perineural Invasion in Aggressive Skin Carcinomas of the Head and Neck

Perineural Invasion in Aggressive Skin Carcinomas of the Head and Neck

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Fatores preditivos do maior número de estádios na cirurgia micrográfica de Mohs para o tratamento do carcinoma espinocelular da cabeça

Contact Info

Product

Resources

About